1	Three-dimensional MRI-based Printed Models of Prostate Anatomy and Targeted		
2	Biopsy-proven Index Tumor to Facilitate Patient-tailored Radical Prostatectomy – a		
3	feasibility study		
4			
5	Christopher Darr1+; Friederike Finis1+; Manuel Wiesenfarth2; Francesco Giganti3,4;		
6	Stephan Tschirdewahn ¹ ; Ulrich Krafft ¹ ; Claudia Kesch ¹ ; David Bonekamp ⁵ ; Michael		
7	Forsting ⁶ ; Axel Wetter ⁶ ; Henning Reis ⁷ ; Boris A. Hadaschik ¹ ; Johannes Haubold ^{5*} ; Jan		
8	Philipp Radtke ^{1,5*}		
9	¹ Department of Urology, University Hospital Essen, Essen, Germany and German Cancer Consortium		
10	(DKTK)-University Hospital Essen, Essen, Germany		
11	² Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany		
12	³ Department of Radiology, University College London Hospitals NHS Foundation Trust, London, UK		
13	⁴ Division of Surgery and Interventional Science, University College London, London, UK		
14	⁵ Department of Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany		
15	⁶ Institute of Diagnostic and Interventional Radiology, University Hospital Essen, Essen, Germany and		
16	German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany		
17	⁷ Institute of Pathology, University Hospital Essen, Essen, Germany and German Cancer Consortium		
18	(DKTK)-University Hospital Essen, Essen, Germany		
19	*shared first authorship		
20	*contributed equally as senior authors		
21			
22			
23			
24			
25			
26			
27	MeSH keywords:		
28	Prostate cancer, MRI, 3D model, MRI-derived printed prostate model, radical		
29	prostatectomy, patient-tailored prostatectomy		

30 Corresponding author:

- 31 PD Dr. med. Jan Philipp Radtke
- 32 Department of Urology
- 33 University Hospital Essen
- 34 Hufelandstr. 55
- 35 45147 Essen, Germany
- 36 E-mail: j.radtke@dkfz-heidelberg.de
- 37 Phone.: 0049 201-723/83069
- 38 Fax.: 0049 201-723/3151
- 39
- 40 <u>Abbreviations:</u>41
- 42 DCE: Dynamic contrast-enhanced Imaging
- 43 DRE: Digital-rectal examination
- 44 EPE: Extraprostatic extension
- 45 ESUR: European Society of Urogenital Radiology
- 46 GGG: Gleason Grade group
- 47 IFS: Intraoperative frozen sectioning
- 48 mpMRI: multiparametric Magnetic Resonance Imaging
- 49 MRI: Magnetic Resonance Imaging
- 50 NSM: Negative surgical margins
- 51 PC: Prostate cancer
- 52 PI-RADS: Prostate Imaging Reporting and Data System
- 53 PSA: Prostate specific antigen
- 54 PSM: Positive surgical margins
- 55 PV: Prostate volume
- 56 RP: Radical prostatectomy
- 57 SB: Systematic biopsy
- 58 sPC: Significant prostate cancer
- 59 STARD: Standards of Reporting of Diagnostic Accuracy
- 60 TRUS: Transrectal ultrasound

61 TV: Tumor volume

62 Abstract

In this prospective single center feasibility study, we demonstrate that the use of 3Dprinted prostate-models support nerve-sparing radical prostatectomy (RP) and intraoperative frozen-sectioning (IFS) in ten men suffering from intermediate- and highrisk prostate cancer (PC), of whom seven harbored pT3-disease. Patient-specific 3D resin models were printed based on preoperative multiparametric MRI (mpMRI) to provide an exact 3D impression of significant tumor lesions. RP and IFS were planned in a patient-tailored fashion.

The 36-region PI-RADSv2.0 scheme was used to compare the MRI/3D-print with whole-mount histopathology. In all cases, the localization of the index lesion was correctly displayed by MRI and the 3D-model. Localization of significant PC lesions correlated significantly (Pearson's correlation coefficient of 0.88 (p<0.001). In addition, a significant correlation of the width, length and volume of the tumor and prostate gland derived from the printed model and histopathology was found, using Pearson's correlation analyses and Bland-Altman plots.

In conclusion, 3D-printed prostate-models correlate well with final pathology and canbe used to tailor RP.

79

80 Patient summary

The use of 3D printed prostate-models based on preoperative MRI may improve prostatectomy outcome. This study confirmed accuracy of 3D printed prostates compared to pathology from RP specimens. Thus, MRI-derived 3D printed prostatemodels can assist prostate cancer surgery.

85

86 Main report:

87 Multiparametric MRI (mpMRI) and transrectal ultrasound (TRUS)-fusion targeted biopsy detect significantly more significant prostate cancers (sPC) than standard 88 89 TRUS-biopsy [1,2]. In addition, high spatial resolution of MRI facilitates precise 90 knowledge of the localization of sPC before nerve-sparing radical prostatectomy (RP), 91 to gain maximum security while reducing burden of erectile dysfunction after RP [3]. 92 Another possible tool is intraoperative frozen sectioning (IFS). Schlomm et al. 93 described that IFS has the potential to significantly increase nerve-sparing and to 94 reduce positive margins (PSM) [4]. In addition, Petralia et al. combined both 95 approaches and could demonstrate that preoperative MRI can guide IFS to significantly reduce PSM [5]. This is of specific interest, as unfavourable PSM (>3 mm 96 97 and/or multifocal) confer a higher oncologic risk of developing metastasis [6]. Another 98 promising step might be utilization of MRI-derived 3D printed prostate models [3].

In our feasibility study we used customized, patient-specific 3D printed prostates. The main purpose was to evaluate the correlation of the index tumor lesion and of all sPC lesions between the 3D-prints and RP specimens. Differences in index lesion dimensions (length, width, volume) and whole gland between MRI-based print models and RP specimens were analysed, as underestimation of the lesion volume by MRI of up to 30% has been demonstrated [7]. Lastly, we investigated the role of MRI/3D-model-directed IFS to decrease the rate of PSM after RP [5].

106

In this feasibility study (review board-approval, 19-TEMP579281-BO, 03/2019-06/2019), ten consecutive patients with clinically localized intermediate- and high-risk
PC underwent a 3-Tesla mpMRI using a Prostate Imaging-Reporting and Data System
(PI-RADS)v2.0-conform protocol and subsequent MRI/TRUS-fusion biopsy. [8].

111 The 3D printed prostates were outlined based on the mpMRI, manually marking the 112 boundaries of the prostate gland and seminal vesicles using the open source software 113 3D-Slicer (version: 4.10.2). Index lesions were defined as the lesion with the highest 114 International Society of Urological Pathology (ISUP) Gleason grading groups (GGG) 115 or the largest volume within a prostate. sPC was defined as ISUP ≥2. Biopsy-proven 116 index lesions on mpMRI and all sPC lesions were contoured manually marked under 117 supervision of a dedicated uro-radiologist with experience > 1000 image reports in 118 prostate MRI (AW). A 3D printer (Anycubic Photon, Shenzhen, China) printed the 119 specimens out of resin whereas the index lesion was left blank or filled with a different 120 color.

121 RP was performed by one experienced surgeon (BAH, >500 cases) using a retropubic 122 or robot-assisted technique. Based on National Comprehensive Cancer Network risk-123 groups (intermediate- and high-risk in the present cohort) and with aid of the 3D-printed 124 models, a nerve-sparing approach and IFS were planned and performed. Specifically, 125 IFS was performed for each index lesion and other sPC lesions. Pathological work-up 126 was performed according to current clinical standards by a dedicated pathologist with 127 12 years of experience in genitourinary-pathology (HR). For the analysis, quarters 128 were digitally reconstructed to whole-mounts. Tumor dimensions were measured using 129 MITK software (Medical Imaging Interaction Toolkit, v2018.04.02). The 3D-printed 130 prostate was sliced at the index lesion with a commercial hacksaw. The correct 131 orientation was achieved by interdisciplinary workup between clinicians and 132 pathologists on an individual case-basis and according to anatomical landmarks of the 133 prostate. Histopathologic slides with the greatest cross-section of the specific lesion 134 were used for agreement analysis of location on T2-weighted images. The slides as 135 well as the T2-weighted images had a 90° flip-angle which was transferred accordingly 136 to the anatomical preparation. Agreement and true positivity of the MRI lesion were

137 considered if there was exact agreement or a discrepancy with the pathologic lesion in
138 up to one region in any direction [7]; correlation was assessed using Pearson's
139 correlation coefficient.

140 Correlation of the dimensions of the index lesion and the prostate volume on 3D-141 printed model and RP specimen was analysed by Pearson's correlation coefficient and 142 graphically by scatter plots and Bland-Altman plots (Figure 1). Statistical analyses were 143 performed using R version 3.5.0 (R Foundation for Statistical Computing, Vienna, 144 Austria) and GraphPad Prism (GraphPad Software, San Diego, USA).

145

146 Patients' demographic and histopathological data are given in Table 1. In all 10 cases, 147 the index lesion of the 3D-print was correctly located considering the 36-region PI-148 RADS scheme compared to histopathology. 13/14 sPC lesions (93%) were also 149 correctly located, resulting in a significant correlation with a Pearson's coefficient of 150 0.88 (p<0.001). Histopathology proved negative surgical margins (NSM) in 7 patients. 151 PSM was found in three men suffering from locally advanced pT3 disease. These 152 matched with the suspected extraprostatic extension (EPE) of MRI and the 3D-printed 153 models. Out of the 3 cases with positive IFS, in two repeat resection demonstrated 154 cancer free tissue out of which final pathology demonstrated PSM in one. In the last 155 case a further resection was not possible due to infiltration of the urethral sphincter.

156

Measurements of tumor and prostate dimensions showed a significant correlation between the 3D-print and histopathology (length: $r^2=0.59$, p=0.01; width: $r^2=0.64$, p=0.005; tumor volume (TV): $r^2=0.52$, p=0.045; prostate volume: $r^2=0.70$, p=0.002). Pathology measurements were multiplied by a correction factor of 1.15 to compensate for tissue shrinkage due to formalin-fixation. Bland-Altman plots emphasize differences on TV between printed models and histopathology. Particularly, large tumors were

underestimated on MRI/3D-print as compared to pathology by up to 30%. Of note, the deviation increased with increasing TV, whereas smaller tumor dimensions had an accurate correlation. These results are in the line with findings by Baco et al., suggesting that mpMRI is able to predict the presence of extra-prostatic disease, rather than representing the EPE by means of volume [9]. Contrary the prostate volume is overrated in the MRI compared to histopathology (Figure 1).

169

Discrepancies of these volume measurements might be caused through different measurement types. Whereas the TV was measured using MITK software, the prostate volume was measured manually using the GE RIS/PACS software (Version 3.0, Chicago, Illinois, USA). Recent literature suggests that computer-assisted TV calculation might attenuate underestimation [10]. Comparison between the histopathologic slide and the sliced 3D-model might be influenced through marginally different heights of the MRI slide and the corresponding histopathologic slide.

Nonetheless, the visual and haptic aid of a 3D-model in an intraoperative setting can lead to more precise IFS. Pre- and intraoperative benefits of a 3D-model approach have been described, namely planning of a patient-tailored RP and training of surgeons undergoing the learning-curve [11,12]. The significant correlation of both, localization and lesion volume between histopathology and 3D-print in our study is crucial for the assumption that applying MRI-derived 3D-models might correctly guide IFS and increase the rate of NSM [6].

184 Chen et al. have recently shown that the use of a fused-deposition-modelling-printer is 185 possible, resulting in much lower cost. Certainly, cost-efficient models which are 186 printed in a short turnaround are favourable for the surgeon [13].

Some limitations of our manuscript merit discussion. Firstly, the number of patients inthis feasibility study is limited. This small number of patients seems justifiable, due to

189 oncologic safety purposes. A strength of the study is that for the first time statistical 190 analyses using correlation coefficients are presented to demonstrate not only 191 feasibility, but also precision of preoperative imaging and 3D-models as compared to 192 RP specimen. Secondly, we investigated only the PSM-rate, and not the more 193 sophisticated surrogate of biochemical recurrence-free survival. However, for a direct 194 analysis of an accurate application of MRI-guided IFS, the SM-status may be sufficient. 195 We did not account for a comparison of a preoperative MRI alone versus MRI-derived 196 3D-models. In view of the recently updated European Association of Urology (EAU) 197 guidelines, knowledge of the preoperative MRI results alone might be sufficient to 198 facilitate patient-tailored RP as recently demonstrated [14,15]. For accurate prediction 199 of EPE, standardized reading using ESUR classification is crucial, as accuracy is 200 decreased by unstandardized MR-reading [14,16]. Lastly, the single-surgeon 201 experience in this feasibility study limits generalizability of the results for cohorts 202 consisting of multiple surgeons with different expertise.

203 **Conflict of interest:**

204 All authors of this manuscript indicate no conflicts of interest regarding the present

205 work.

206 References

207	[1]	van der Leest M, Cornel E, Israël B, Hendriks R, Padhani AR, Hoogenboom M,
208		et al. Head-to-head Comparison of Transrectal Ultrasound-guided Prostate
209		Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent
210		Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated
211		Prostate-specific Antigen: A Large Prospective Mu. Eur Urol 2019;75:570-8.
212		doi:10.1016/j.eururo.2018.11.023.
213	[2]	Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA,
214		Vaarala MH, et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer
215		Diagnosis. N Engl J Med 2018;318:1767–77. doi:10.1056/NEJMoa1801993.
216	[3]	Shin T, Ukimura O, Gill IS. Three-dimensional Printed Model of Prostate
217		Anatomy and Targeted Biopsy-proven Index Tumor to Facilitate Nerve-sparing
218		Prostatectomy. Eur Urol 2016;69:377–9. doi:10.1016/j.eururo.2015.09.024.
219	[4]	Schlomm T, Tennstedt P, Huxhold C, Steuber T, Salomon G, Michl U, et al.
220		Neurovascular Structure-adjacent Frozen-section Examination (NeuroSAFE)
221		Increases Nerve-sparing Frequency and Reduces Positive Surgical Margins in
222		Open and Robot-assisted Laparoscopic Radical Prostatectomy : Experience
223		After 11 069 Consecutive Patients. Eur Urol 2012;62:333-40.
224	[5]	Petralia G, Musi G, Padhani A, Summers P, Renne G, Alessi S, et al. Robot-
225		assisted Radical Prostatectomy : Multiparametric MR Imaging-directed
226		Intraoperative Frozen-Section Analysis to Reduce the Rate of Positive Surgical
227		Margins. Radiology 2015;274:434–44.
228	[6]	Martini A, Gandaglia G, Fossati N, Scuderi S, Bravi CA, Mazzone E, et al.
229		Defining Clinically Meaningful Positive Surgical Margins in Patients Undergoing
230		Radical Prostatectomy for Localised Prostate Cancer. Eur Urol Oncol 2019.
231		doi:10.1016/j.euo.2019.03.006.

- 232 [7] Radtke JP, Schwab C, Wolf MB, Freitag MT, Alt CD, Kesch C, et al.
- 233 Multiparametric Magnetic Resonance Imaging (MRI) and MRI Transrectal
- 234 Ultrasound Fusion Biopsy for Index Tumor Detection: Correlation with Radical
- Prostatectomy Specimen. Eur Urol 2016;70:846–53.
- 236 doi:10.1016/j.eururo.2015.12.052.
- 237 [8] Barentsz JO, Weinreb JC, Verma S, Thoeny HC, Tempany CM, Shtern F, et al.
- 238 Synopsis of the PI-RADS v2 Guidelines for Multiparametric Prostate Magnetic
- 239 Resonance Imaging and Recommendations for Use. Eur Urol 2015:1–9.
- 240 doi:10.1016/j.eururo.2015.08.038.
- 241 [9] Baco E, Rud E, Vlatkovic L, Svindland A, Eggesbø HB, Hung AJ, et al.
- 242 Predictive value of Magnetic Resonance Imaging Determined Tumor Contact
- 243 Length for Extra-capsular Extension of Prostate cancer. J Urol 2014;193:466–
- 244 72. doi:10.1016/j.juro.2014.08.084.
- [10] Marin L, Ezziane M, Comperat E, Mozer P, Cancel-Tassin G, Coté JF, et al.
- 246 Comparison of semi-automated and manual methods to measure the volume
- of prostate cancer on magnetic resonance imaging. Diagn Interv Imaging
- 248 2017;98:423–8. doi:10.1016/j.diii.2017.02.004.
- 249 [11] Cacciamani GE, Okhunov Z, Meneses AD, Rodriguez-Socarras ME, Rivas JG,
- 250 Porpiglia F, et al. Impact of Three-dimensional Printing in Urology: State of the
- Art and Future Perspectives. A Systematic Review by ESUT-YAUWP Group.
- 252 Eur Urol 2019;76:209–21. doi:10.1016/j.eururo.2019.04.044.
- 253 [12] Porpiglia F, Bertolo R, Checcucci E, Amparore D, Autorino R, Dasgupta P, et
- al. Development and validation of 3D printed virtual models for robot-assisted
- 255 radical prostatectomy and partial nephrectomy: urologists' and patients'
- 256 perception. World J Urol 2018;36:201–7. doi:10.1007/s00345-017-2126-1.
- 257 [13] Chen MY, Skewes J, Woodruff MA, Dasgupta P, Rukin. Multi-material

- extrusion fused deposition modelling: a low-cost 3D printing method for
 anatomical prostate cancer models. Sci Rep 2020;10. doi:10.1038/s41598020-67082-7.
- 261 [14] Morlacco A, Sharma V, Viers BR, Rangel LJ, Carlson RE, Froemming AT, et
- al. The Incremental Role of Magnetic Resonance Imaging for Prostate Cancer
- 263 Staging before Radical Prostatectomy. Eur Urol 2016:8–11.
- 264 doi:10.1016/j.eururo.2016.08.015.
- 265 [15] Mottet N, van den Bergh R, Briers E, Cornford P, De Santis M, Fanti S, et al.
- 266 EAU EANM ESTRO ESUR SIOG Guidelines on Prostate Cancer 2019.
- 267 Eur Assoc Urol Guidel 2019;Edn. prese.
- 268 [16] Nyarangi-Dix J, Wiesenfarth M, Bonekamp D, Hitthaler B, Schütz V,
- 269 Dieffenbacher S, et al. Combined Clinical Parameters and Multiparametric
- 270 Magnetic Resonance Imaging for the Prediction of Extraprostatic Disease—A
- 271 Risk Model for Patient-tailored Risk Stratification When Planning Radical
- 272 Prostatectomy. Eur Urol Focus 2018:4–11. doi:10.1016/j.euf.2018.11.004.
- 273

- 274 Table legends:
- 275 <u>Table 1:</u>
- 276 Patient demographics and histopathologic characteristics.
- 277
- 278 Supplementary Material legends:
- 279 Supplementary Material 1:
- 280 Standards of Reporting of Diagnostic Accuracy (STARD) checklist
- 281
- 282 Figure legends:
- 283 Figure 1:

Figure 1A. Evaluation of different dimension modalities of the tumor and prostate comparing 3D-print/MRI with histopathology. For each analysis Scatter plots (left) and Bland-Altman plots have been performed. The red line shows the ideal line. The black line displays the balancing line. 1: Length of the tumor ($r^2 = 0.59$; p = 0.01), 2: Width of the tumor ($r^2 = 0.64$; p = 0.005), 3: Volume of the tumor ($r^2 = 0.52$; p = 0.045), 4: Volume of the prostate ($r^2 = 0.70$; p = 0.002).

Figure 1B. All four images are taken from the same prostate. This prostate is printed out of liquid photopolymer cured through UV light, the tumor is presented in red photopolymer and more cured than the rest of the prostate. 1: mpMRI of the prostate with index lesion (caudal view), 2: 3D printed prostate with index lesion (photo is taken from caudal), 3: histopathology of the prostate with index lesion (caudal view) 4: 3D printed prostate with index lesion (cranio-dorsal view).